Results 321 to 330 of about 299,239 (347)

Impact of the COVID-19 pandemic on unfavorable tuberculosis outcomes: a comparative analysis of unhoused and general populations. [PDF]

BMC Public Health
da Silva Campana P, da Silva ATC, Klautau GB, Rujula MJP, Salles MJ, de Castro MC.   +5 more
europepmc   +1 more source

Correction to 'Initiation of Anticoagulants During the COVID-19 Pandemic in Sweden: An Interrupted Time Series Analysis'. [PDF]

Basic Clin Pharmacol Toxicol
europepmc   +1 more source

Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19

Schilling WH, Jittamala P, Wongnak P, Watson JA, Boyd S, Luvira V, Siripoon T, Ngamprasertchai T, Batty EM, Beer E, Singh S, Asawasriworanan T, Seers T, Phommasone K, Evans TJ, Kruabkontho V, Ngernseng T, Tubprasert J, Abdad MY, Madmanee W, Kouhathong J, Suwannasin K, Pagornrat W, Piteekan T, Hanboonkunupakarn B, Poovorawan K, Potaporn M, Srisubat A, Loharjun B, Chotivanich K, Imwong M, Pukrittayakamee S, Dondorp AM, Day NP, Piyaphanee W, Phumratanaprapin W, White NJ.   +36 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Drugs for the Treatment of COVID-19

2021
Currently, there are no drugs or other therapeutic agents approved by the U.S. Food and Drug Administration (FDA) to prevent or treat COVID-19. Current standard of care includes prevention of infection and control measures and supportive care, including supplemental oxygen and, when required, mechanical ventilatory support.
Sagheer Ahmed, Halimur Rehman, M. Tauseef Sultan, Rehan Salar, Marius Moga, May Bin-Jumah   +5 more
openaire   +2 more sources

Investigational antiviral drugs for the treatment of COVID-19

Drugs of the Future, 2021
A large number of candidate drugs are undergoing evaluation for their potential to limit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication. Clinical trial data are slowly emerging for several of these agents. We provide a review of candidate antiviral agents registered in ClinicalTrials.gov, which have clinical efficacy data ...
V. Koblizek, K. Burke, R. Talwani, M. Assi, Zelalem Temesgen, C. T. R. Vegivinti   +5 more
openaire   +2 more sources

COVID-19 drug discovery and treatment options

Nature Reviews Microbiology
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused substantial morbidity and mortality, and serious social and economic disruptions worldwide. Unvaccinated or incompletely vaccinated older individuals with underlying diseases are especially prone to severe disease.
Jasper Fuk-Woo Chan, Shuofeng Yuan, Hin Chu, Siddharth Sridhar, Kwok-Yung Yuen   +4 more
openaire   +2 more sources

Cancer treatment and survivorship statistics, 2022

Ca-A Cancer Journal for Clinicians, 2022
Kimberly D Miller, Leticia Nogueira, Angela B Mariotto   +2 more
exaly  

Current treatment and recent progress in gastric cancer

Ca-A Cancer Journal for Clinicians, 2021
Smita S Joshi, Brian D Badgwell
exaly  

Integrative oncology: Addressing the global challenges of cancer prevention and treatment

Ca-A Cancer Journal for Clinicians, 2022
Paulo Cáceres Guido, Jun J Mao, Lorenzo Cohen   +2 more
exaly